A new type of vaccine provides protection against a variety of SARS-like betacoronaviruses, including COVID-19 variants, in mice and monkeys, according to a new study by Caltech.
Betacoronaviruses, including those that caused the SARS, MERS, and COVID-19 pandemics, are a specific type of coronaviruses that infect humans and animals. The new vaccine works to induce the production of a broad spectrum of cross-reactive antibodies by presenting the immune system with pieces of the spike proteins from SARS-CoV-2 (the virus that causes COVID-19) and seven other SARS-like betacoronaviruses, attached to a protein nanoparticle structure. Notably, when vaccinated with this so-called mosaic nanoparticle, animal models were protected from an additional coronavirus, SARS-CoV, which was not one of the eight represented on the nanoparticle vaccine.
“Animals vaccinated with the mosaic-8 nanoparticles elicited antibodies that recognized virtually every SARS-like betacoronavirus strain we evaluated,” says Caltech postdoctoral scholar Alexander Cohen (PhD ’21), co-first author of the new research. “Some of these viruses could be related to the strain that causes the next SARS-like betacoronavirus outbreak, so what we really want would be something that targets this entire group of viruses. We believe we have that.”
The research was published on July 5 in a paper in the journal Science. The study led by researchers in the laboratory of Caltech’s Pamela Bjorkman, the David Baltimore Professor of Biology and Bioengineering.
“SARS-CoV-2 has proven itself capable of making new variants that could prolong the global COVID-19 pandemic,” says Bjorkman, who is also a Merkin Institute Professor and executive officer for Biology and Biological Engineering. “In addition, the fact that three betacoronaviruses—SARS-CoV, MERS-CoV, and SARS-CoV-2—have spilled over into humans from animal hosts in the last 20 years illustrates the need for making broadly protective vaccines.”
According to Bjorkman, such broad protection is needed “because we can’t predict which virus or viruses among the vast numbers in animals will evolve in the future to infect humans to cause another epidemic or pandemic. What we’re trying to do is make an all-in-one vaccine protective against SARS-like betacoronaviruses regardless of which animal viruses might evolve to allow human infection and spread. This sort of vaccine would also protect against current and future SARS-CoV-2 variants without the need for updating.”
How it works: A vaccine composed of spike domains from eight different SARS-like coronaviruses
The vaccine technology to attach pieces of a virus to protein nanoparticles was developed initially by collaborators at the University of Oxford. The basis of the technology is a tiny cage-like structure (a “nanoparticle”) made up of proteins engineered to have “sticky” appendages on its surface, upon which researchers can attach tagged viral proteins. These nanoparticles can be prepared to display pieces of one virus only (“homotypic” nanoparticles) or pieces of several different viruses (“mosaic” nanoparticles). When injected into an animal, the nanoparticle vaccine presents these viral fragments to the immune system. This induces the production of antibodies, immune system proteins that recognize and fight off specific pathogens, as well as cellular immune responses involving T lymphocytes and innate immune cells.
In this research study, the scientists chose eight different SARS-like betacoronaviruses—including SARS-CoV-2, the virus that has caused the COVID-19 pandemic, along with seven related animal viruses that could have potential to start a pandemic in humans—and attached fragments from those eight viruses onto the nanoparticle scaffold. The team chose specific fragments of the viral structures, called receptor-binding domains (RBDs), that are critical for coronaviruses to enter human cells. In fact, human antibodies that neutralize coronaviruses primarily target the virus’s RBDs.
The idea is that such a vaccine could induce the body to produce antibodies that broadly recognize SARS-like betacoronaviruses to fight off variants in addition to those presented on the nanoparticle by targeting common characteristics of viral RBDs. This design comes from the idea that the diversity and physical arrangement of RBDs on the nanoparticle will focus the immune response toward parts of the RBD that are shared by the entire SARS family of coronaviruses, thus achieving immunity to all. The data reported in Science today demonstrates the potential efficacy of this approach.
Designing experiments to measure the vaccine’s protection in mice
The resulting vaccine (here dubbed mosaic-8) is composed of RBDs from eight coronaviruses. Previous experiments led by the Bjorkman lab showed that mosaic-8 induces mice to produce antibodies that react to a variety of coronaviruses in a lab dish (Cohen et al., 2021, Science). Led by Cohen, the new study aimed to build from this research to see if vaccination with the mosaic-8 vaccine could induce protective antibodies in a living animal upon challenge (in other words, infection) with SARS-CoV-2 or SARS-CoV.
The scientists aimed to compare how much protection against infection was provided by a nanoparticle covered in different coronavirus fragments (mosaic-8) versus a nanoparticle covered in only fragments of SARS-CoV-2 (a “homotypic” nanoparticle).
Three sets of experiments were conducted on mice. In one, the control, they inoculated mice with just the bare nanoparticle cage structure without any virus fragments attached. A second group of mice were each injected with a homotypic nanoparticle covered only in SARS-CoV-2 RBDs, and a third group was injected with mosaic-8 nanoparticles. One experimental goal was to see if inoculation with mosaic-8 would protect the animals against SARS-CoV-2 to the same degree as the homotypic SARS-CoV-2-immunized animals; a second goal was to evaluate protection from a so-called “mismatched virus”—one that was not represented by an RBD on the mosaic-8 nanoparticle.
Notably, the eight strains of coronavirus covering the mosaic nanoparticle intentionally did not include SARS-CoV, the virus that caused the original SARS pandemic in the early 2000s. Thus, the team aimed to also investigate the degree of protection against a challenge with the original SARS-CoV virus, using it to represent an unknown SARS-like betacoronavirus that could spill over into humans.
The mice used in the experiments were genetically engineered to express the human ACE2 receptor, which is the receptor on human cells that is used by SARS-CoV-2 and related viruses to gain entry into cells during infection. In this animal challenge model, unvaccinated mice die if infected with a SARS-like betacoronavirus, thus providing a stringent test to evaluate the potential for protection from infection and disease in humans.
Mosaic vaccine protects mice against a similar SARS-like betacoronavirus
As expected, mice inoculated with the bare nanoparticle structure did die when infected with SARS-CoV or SARS-CoV-2. Mice that were inoculated with a homotypic nanoparticle only coated in SARS-CoV-2 RBDs were protected against SARS-CoV-2 infection but died upon exposure to SARS-CoV. These results suggest that current homotypic SARS-CoV-2 nanoparticle vaccine candidates being developed elsewhere would be effective against SARS-CoV-2 but may not protect broadly against other SARS-like betacoronaviruses crossing over from animal reservoirs or against future SARS-CoV-2 variants.
However, all of the mice inoculated with mosaic-8 nanoparticles survived both the SARS-CoV-2 and SARS-CoV challenges with no weight loss or other significant pathologies.
Nonhuman primate research also confirms the mosaic vaccine’s efficacy
The team then performed similar challenge experiments in nonhuman primates, this time using the most promising vaccine candidate, mosaic-8, and comparing the effects of mosaic-8 vaccination versus no vaccination in animal challenge studies. When inoculated with mosaic-8, the animals showed little to no detectable infection when exposed to SARS-CoV-2 or SARS-CoV, again demonstrating the potential for the mosaic-8 vaccine candidate to be protective for current and future variants of the virus causing the COVID-19 pandemic as well as against potential future viral spillovers of SARS-like betacoronaviruses from animal hosts.
Importantly, in collaboration with virologist Jesse Bloom (PhD ’07) of the Fred Hutchinson Cancer Research Center, the team found that antibodies elicited by mosaic-8 targeted the most common elements of the RBDs across a diverse set of other SARS-like betacoronaviruses—the so-called “conserved” part of the RBD—thus providing evidence for the hypothesized mechanism by which the vaccine would be effective against new variants of SARS-CoV-2 or animal SARS-like betacoronaviruses. By contrast, homotypic SARS-CoV-2 nanoparticle injections elicited antibodies against mainly strain-specific RBD regions, suggesting these types of vaccines would likely protect against SARS-CoV-2 but not against newly arising variants or potential emerging animal viruses.
As a next step, Bjorkman and colleagues will evaluate mosaic-8 nanoparticle immunizations in humans in a Phase 1 clinical trial supported by the Coalition for Epidemic Preparedness Initiative (CEPI). To prepare for the clinical trial, which will largely enroll people who have been vaccinated and/or previously infected with SARS-CoV-2, the Bjorkman lab is planning preclinical animal model experiments to compare immune responses in animals previously vaccinated with a current COVID-19 vaccine to responses in animals that are immunologically naïve with respect to SARS-CoV-2 infection or vaccination.
“We have talked about the need for diversity in vaccine development since the very beginning of the pandemic,” says Dr. Richard J. Hatchett, CEO of CEPI. “The breakthrough exhibited in the Bjorkman lab study demonstrates huge potential for a strategy that pursues a new vaccine platform altogether, potentially overcoming hurdles created by new variants. I am delighted to announce that CEPI will be supporting this novel approach to pandemic prevention in Phase I clinical trials. The accelerated speed the study achieved after receiving Wellcome Leap funding facilitated our relationship with them today. The non-human primate data is extremely encouraging and we’re excited to support the next phase of trials.”
Reference: “Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models” by Alexander A. Cohen, Neeltje van Doremalen, Allison J. Greaney, Hanne Andersen, Ankur Sharma, Tyler N. Starr, Jennifer R. Keeffe, Chengcheng Fan, Jonathan E. Schulz, Priyanthi N. P. Gnanapragasam, Leesa M. Kakutani, Anthony P. West, Greg Saturday, Yu E. Lee, Han Gao, Claudia A. Jette, Mark G. Lewis, Tiong K. Tan, Alain R. Townsend, Jesse D. Bloom, Vincent J. Munster and Pamela J. Bjorkman, 5 July 2022, Science.
Wellcome Leap provided critical funding at a crucial time to accelerate the development of the Caltech technology, shortening the timeline to reach Phase 1 clinical trials by more than 18 months. Regina E. Dugan (PhD ’93), CEO of Wellcome Leap, says, “This early transition success demonstrates the value of global partnerships working collaboratively and with the urgency needed to address future pandemic risks.”
The paper is titled “Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.” Neeltje van Doremalen of the National Institute of Allergy and Infectious Diseases (National Institutes of Health) Rocky Mountain Laboratories is a co-first author along with Cohen.
Additional Caltech co-authors are Jennifer Keeffe, research scientist; Chengcheng Fan, postdoctoral scholar research associate in Biology and Biological Engineering; Priyanthi Gnanapragasam, research technician; former research technician Leesa Kakutani; Anthony P. West Jr., senior research specialist; former research technician Yu Lee; Han Gao, research technician; and former graduate student Claudia Jette (PhD ’22).
Other co-authors are Allison Greaney, Tyler Starr, and Jesse Bloom of the Fred Hutchinson Cancer Research Center; Hanne Andersen, Ankur Sharma, and Mark Lewis of BIOQUAL; Jonathan Schulz, Greg Saturday, and Vincent Munster of the Rocky Mountain National Laboratories; and Tiong Tan and Alain Townsend of the University of Oxford.
This preclinical vaccine validation study was funded by Wellcome Leap, and built directly on initial development and proof-of-principle studies funded early in the pandemic by Caltech’s Merkin Institute for Translational Medicine. Other ongoing coronavirus work in the Bjorkman group is supported by the Bill and Melinda Gates Foundation and George Mason Fast Grants.
Be the first to comment on "Caltech’s Nanoparticle Vaccine Protects Against a Wide Range of COVID-19-Causing Variants and Related Viruses"